INTRODUCTION
Despite ongoing progress in the development of targeted therapeutics such as monoclonal antibodies and small molecule kinase inhibitors, the mortality of cancer continues to be very high. 1 Gene therapy has the potential to become a very valuable additional treatment option for this disease. Although our increasing understanding of the molecular mechanisms of tumor pathobiology has prompted the exploration of various promising therapeutic gene candidates such as tumor suppressor genes, immunomodulatory genes or cytotoxic and suicide genes, 2,3 most of the available vector systems are still poorly suited for systemic application in cancer treatment.
Like for all other vector systems, the clinical use of vectors based on adeno-associated virus (AAV) is mainly limited by their low transduction efficiency of the target tissue and the unintended transduction of non-target tissues. Several strategies have been developed to engineer AAV capsids with improved transduction efficiency and specificity for certain cell types or tissues (reviewed in Michelfelder and Trepel 4 ) and minimized unintended vector-directed immunoreactions. [5] [6] [7] Many of these targeting approaches for AAV vectors are based on incorporation of targeting peptides, preferentially at capsid positions critical for receptor binding. [8] [9] [10] Incorporation of peptide ligands into the AAV2 capsid can abrogate the natural tropism of AAV toward the liver and at the same time mediate transduction of alternative cell types or tissues. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The design of such targeting ligands, however, remains challenging. Also, their efficacy is often limited by the fact that most of them have been selected exclusively for cell binding and not for their compatibility with efficient cell entry, intracellular processing and gene expression of the vector. In vivo biopanning of random AAV display peptide libraries addresses these issues. It takes into account specific ligand-receptor interactions under circulating conditions, accessibility of target cells and their receptors to the circulating ligands as well as vector clearance from the circulation by the reticuloendothelial system. 21 This approach has yielded vector capsids displaying unique peptide motifs with improved gene transfer efficiency to the target tissues of interest. 16, [22] [23] [24] Nevertheless, transgene expression mediated by such vectors could not be completely restricted to the target tissue so far. Although some targeting ligands, such as the ESGLSQS peptide which had been selected within the context of an AAV2 library, could be transferred into the threefold-spike domain of the AAV9 capsid without losing their targeting properties toward the tissue of interest, 25 a certain degree of preserved natural tropism, especially toward the heart, 11 has remained in most vectors selected from AAV libraries in vivo so far. 16, 25 However, absolute target specificity of viral vectors in many settings is mandatory for their clinical use, especially in applications such as cancer in which cytotoxic transgenes may have to be delivered. This major limitation of the otherwise outstanding potential of AAV libraries has not been solved yet. To address this problem, we applied a strategy based on tissue-specific post-transcriptional regulation of gene expression by insertion of complementary target elements for microRNA like it has been explored in different settings based on lentivirus, 26 adenovirus 27 or AAV. 28, 29 A combinatory approach of receptordirected and microRNA-mediated targeting of rAAV vectors has not been explored before, thus we validated the therapeutic potential of this strategy in an in vivo model requiring the highest levels of target tissue transduction (non-localized malignant tumor tissue) and specificity (cytotoxic transgene delivery).
RESULTS AND DISCUSSION
Target-specific gene expression in multifocal breast tumors in vivo mediated by capsid-modified, microRNA-regulated AAV vectors Tropism-modified AAV2 vectors have been recently selected by in vivo screening of random AAV peptide libraries to target therapeutic genes to multifocal breast cancer in PyMT transgenic mice. 16 Vectors displaying the selected peptide ESGLSQS very efficiently re-direct gene expression to breast cancer tissue after systemic administration but the natural tropism of the capsid toward the heart was not entirely abrogated. 16 Since we speculated that gene therapy in the aggressive PyMT tumor model would require highest levels of transgene expression, we used the strong but unspecific cytomegaly virus (CMV) promoter instead of a tumorspecific one. This was also done because we found the tumorspecific hTERT and the MMTV promoter to be much less active than the CMV promoter in primary PyMT cells in vitro (data not shown). In addition, the CMV promoter was favored because of its comparably small size, taking into account the limited packaging capacity of AAV. Thus, we set out to analyze whether transgene expression mediated by capsid modified AAV vectors can be regulated by heart-specific miRNA to suppress transgene expression in this frequent off-target organ without affecting expression in the relevant tumor tissue. We generated AAV vectors containing four repeats of a heart specific miR-1d target element (miRT-1d) following the scheme shown in Figure 1a .
Targeted luciferase reporter gene vectors harboring miRT-1d in forward and reverse orientation (as controls) were generated and orientation of the target element was verified by sequencing (data not shown). Vectors were then produced to sufficient titers, injected intravenously into PyMT transgenic mice bearing multifocal breast carcinomas, and luciferase expression was analyzed ( Figure 1b ). Irrespective of the orientation of miRT-1d, we observed strong gene expression in the tumor tissue. Only moderate gene transduction was detected in the liver and the skeletal muscle, while expression levels in lung, kidney, spleen and brain were at the background level. In animals injected with AAV reporter vectors harboring a miRT-1d binding domain in forward orientation, cardiac reporter gene expression was significantly decreased to a weak expression level, comparable that seen in the liver. Previously, we have shown that AAV9 vectors displaying the peptide ESGLSQS at amino acid position 589 are superior regarding transduction of PyMT-induced breast tumors 25 compared with AAV2 vectors displaying the same peptide at position R588 of their capsid protein. Thus, dual-targeted luciferase vectors based on AAV9 (AAV9-ESGLSQS-miRT-1d) and controls were generated and gene expression was analyzed by bioluminescence imaging in vivo (Figure 1c ), and by bioluminescence imaging from tissues dissected from transduced animals ( Figure 1d ). Although non-targeted AAV9 wild-type vectors mediated strong bioluminescence in liver and heart, only very little transgene expression was detectable in tumor tissue. As expected, insertion of the peptide ESGLSQS into the AAV9 capsid resulted in strong transduction of multifocal tumors localized along the mammary glands, accompanied by an effective detargeting from the liver but sustained transgene expression in the heart. Animals injected with targeted AAV9 luciferase vectors harboring miRT-1d (AAV9-ESGLSQS-miRT-1d), on the other hand, showed a striking reduction of cardiac transgene expression ( Figures 1c and d) , comparable to the degree in other settings utilizing miR-regulated AAV vectors. 28, 29 In contrast, the strong transgene expression in tumor tissue was not affected by miRT-1d, which is in line with the observation that miR-1 family members seem to be deregulated in different cancer entities. 30 Abrogation of cardiotoxicity in mice treated with capsid-modified, miR-1d-regulated cytotoxic AAV vectors To investigate if the heart-specific suppression of transgene expression mediated by dual-targeted AAV vectors is sufficient to circumvent serious cardiotoxic side-effects upon a potential cytotoxic anti-tumor treatment, we produced ESGLSQSdisplaying AAV9 vectors harboring the herpes simplex virus thymidine kinase (HSVtk) suicide gene. A single dose (5 × 10 11 vector genomes (vg) per animal) of cytotoxic vector with or without miR-1d target element was administered intravenously into healthy FVB/N mice. After 4 days, ganciclovir (GCV) treatment was initiated. Two weeks after vector administration, after the fifth cycle of GCV treatment, animals in the group without miRT-1d started to substantially lose weight (410% over night). Thus, the experiment was stopped and animals of all groups were assessed for cardiotoxicity. Echocardiography revealed a significant and clinically relevant reduced ejection fraction (16 ± 3.6%, mean ± s.e.m., P o0.001) in mice treated with cytotoxic vectors without miR-1d target elements, whereas animals treated with cytotoxic vectors equipped with miR-1d target elements showed no cardiac abnormalities when compared with phosphate-buffered saline (PBS)-treated mice (Figure 2a ). Furthermore, left-ventricular enddiastolic diameters was slightly increased ( Figure 2b ) and heart weight to tibia length was significantly (P o 0.03) decreased ( Figure 2c ), whereas no cardiac abnormalities were detected in animals treated with cytotoxic vectors equipped with miR-1d target elements when compared with PBS-treated mice. These findings suggest that animals treated with cytotoxic vectors equipped with miR-1d target elements were protected from gene transfer-and drug-induced dilative cardiomyopathy.
Inhibition of tumor growth in multifocal breast tumors in vivo by a therapeutic suicide gene delivered by miRT-1d regulated and capsid modified AAV9 vectors Having successfully eliminated unintended gene transfer to nontumor tissue by dual-targeted microRNA-regulated ESGLSQS displaying vectors, we analyzed their therapeutic utility. This was done in a challenging therapeutic setting requiring utmost vector specificity and efficiency. We used the PyMT mouse model, 31 which is characterized by multifocal and very-aggressive cancer growth and treated with vectors harboring a variant of the HSV-tk suicide gene. Dual-targeted cytotoxic vector (AAV9-ESGLSQS--4xmiRT-1d-HSVtk) and miRT-1d-regulated cytotoxic wild-type AAV9 vector (AAV9-wild-type-4xmiRT-1d-HSVtk) as control were injected at the animal's age of 10 weeks, when PyMT-induced multifocal tumors reached a size of~50mm 3 . A single vector dose of 5 × 10 11 vg per animal was administered intravenously and GCV treatment was initiated 4 days later (Figure 3a ). After four cycles of GCV treatment, the tumor volume of mice that received dualtargeted cytotoxic vector was already significantly (P o 0.005) smaller than in the control group of mice treated with PBS ( Figure 3b ). Moreover, during the remaining experiment, tumor growth of mice treated with targeted suicide vectors was considerably suppressed compared with the PBS-treated control cohort. Because of extensive and rapid tumor growth in the PBS control mice, the experiment was terminated after 21 days. At this time point (that is, after eight cycles of GCV treatment), the tumor volume of mice treated with AAV9-ESGLSQS-miRT-1d-HSVtk was 0.51 ± 0.12 cm 3 (n = 8) compared with 3.4 ± 0.81 cm 3 for the PBStreated control group (n = 10). To complement the tumor volume data obtained by caliper measurement, we determined the weight of excised tumors. Here again, we found a significantly suppressed tumor growth in animals treated with targeted suicide vectors (tumor weight 0.65 ± 0.11 g, treated (n = 5) vs 1.54 ± 0.41 g, control group (n = 10)) ( Figure 3c ). The tumors of treated mice were 85% smaller than the tumors of mice within the PBS control group at the end of the experiment 21 days after vector administration. Considering that the PyMT mouse model is an aggressive transgenic mouse model in which every single cell of the mammary epithelium will eventually become malignant, the observed effect of inhibited tumor growth fully met our expectations, because complete and sustained eradication of tumor tissue seems to be unrealistic in this setting. In that regard, our dual-targeted suicide gene delivery approach presented here yields similar tumorsuppressive efficiency to other tumor-directed therapies in this model. [32] [33] [34] Thus, the vector applied here broadens the spectrum of valuable treatment options for multifocal cancer and emphasizes the potential of capsid and transcriptional targeting for cancer-directed gene therapy.
Reduction of side effects in tumor-bearing PyMT mice treated with dual-targeted cytotoxic AAV vectors Animals treated with dual-targeted AAV9 vectors kept a stable weight during cytotoxic gene therapy, whereas animals treated In vivo bioluminescence imaging of luciferase expression in PyMT mice bearing multifocal breast tumors. AAV9 vectors displaying the ESGLSQS peptide with or without miRT-1d or wild-type control vectors harboring a luciferase reporter gene were injected intravenously. Images were taken 14 days after vector injection, when bioluminescence reached peak values after intraperitoneal administration of luciferin. (d) Bioluminescence analysis of single organs and multifocal tumors after injection of targeted and non-targeted vectors with or without miRT-1d. Luciferin substrate was administered intraperitoneally 14 days after vector injection. Tumors, lung, liver and heart were removed and images were taken when bioluminescence reached peak values.
with miRT-1d-regulated wild-type AAV9 control vectors showed a significant loss of weight (Figure 4a ), most likely due to strong hepatotoxic effects, resulting in elevated levels of aspartate-amino transferase (ASAT) (Figure 4b ). The experiment within the cohort of control vector-treated mice had to be terminated after 7 days because of massive weight loss and deterioration of the animal's general condition, according to the animal protection code. Nephrotoxicity, on the other hand, did not seem to be problematic for the animals in any of the cohorts, since normal creatinin levels were measured for all animals (Figure 4c ). To further investigate potential side effects of the cytotoxic anti-tumor therapy with the dual-targeted vectors, we performed histopathological analysis of PyMT tumors and control tissues recovered at the end of the therapy. Hematoxylin and eosin staining (H&E) of tumor tissue revealed necrotic lesions derived from tumor destruction caused by targeted treatment with HSVtk and GCV. In contrast, no toxic effects in tumor tissue could be detected in PBS-and control vector-treated animals. Strong hepatotoxic effects, on the other hand, were visible in the group of mice treated with vectors carrying AAV9 wild-type capsids, already after one cycle of GCV treatment. No signs of liver toxicity were seen in mice treated with PBS or the dual-targeted vector. Also, no signs of toxicity were detected in cardiac tissue of mice from any of the groups (Figure 4d ), confirming the therapeutically relevant suppression of cardiac HSVtk expression by the miR-1d binding domain shown in previous experiments. Although capsid localization to the heart was unaltered, we were able to suppress transgene expression in this off-target organ. Capsid-modified AAVs have been proposed to be less immunogenic; 35, 36 however, prevention of a potential capsid-directed cytotoxic T-cell response, like it has been observed in clinical trials in liver and muscles (reviewed in Basner-Tschakarjan and Mingozzi 37 ), might require additional measures if transferring this dual-targeting approach into the clinic. Transient immunosuppression has been shown to be a valuable option in preclinical studies 38, 39 and recently, the potential of modulating the immune response by regulatory T-cells has been evaluated in vitro. 40 Taken together, the comparably strong inhibition of tumor growth in the challenging PyMT mouse model in absence of serious side effects (indicated by the stability of weight, creatinine and ASAT as well as the histology of heart and liver tissue) demonstrates the feasibility of cytotoxic gene transfer by dualtargeted AAV vectors such as the one presented here. 
MATERIALS AND METHODS
Cell culture HEK293T and HeLa cells were grown in DMEM (Life Technologies, Frankfurt, Germany) supplemented with 1% penicillin/streptomycin solution (Life Technologies) and 10% fetal calf serum (Biochrom, Berlin, Germany). All cells were grown at 37°C in a humidified atmosphere with 5% CO 2 .
Animals
Polyoma middle T transgenic mice (PyMT, strain FVB/N-TgN (MMTVPyVT)634-Mul) were obtained from Jackson Laboratory (Bar Harbor, ME, USA). All procedures involving animals were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and the German Animal Protection Code. Approval was granted by the local ethics review board. Genotyping of PyMT transgenic mice was performed as described previously. 16 Blood samples were collected from the retrobulbar venous plexus under anesthesia (2% isoflurane, 98% oxygen). Tumor volumes were calculated after caliper measurement of two diameters using the equation for ellipsoid tumors: tumor volume = ½ (length × width 2 , expressed as mean tumor volume. 41 Plasmids AAV-vector plasmids sensitive to tissue-specific micro RNAs were generated by insertion of DNA fragments containing four repeats of a miR-1d target element (miRT-1d) into the 3`UTR region of the CMV-driven luciferase-expression plasmid pAAV-CMV-luc. pAAV-CMV-luc was generated by Kpn1/Mlu1 excision of the CMV promoter from pcDNA4/TO (Invitrogen, Carlsbad, CA, USA) and blunt ligated into Nhe1/Nco1-digested pGL3-luc (Promega, Mannheim, Germany). Finally, the complete CMV luciferase fragment was released by Cla1/Pvu1 digest and ligased with blunt ends into Not1-digested pAAV-MCS (Stratagene, La Jolla, CA, USA).
Oligonucleotides containing four concatamers of heart-specific miRT-1d (ref. 42) 5′ggccggccAATACATACTTCTTTACATTCCAcgatAA TACATACTTCTTTACATTCCAaccggtAATACATACTTCTTTACATTCCAtc acAATACATACTTCTTTACATTCCAggccggcc′3 and respective antisene (Metabion, Martinsried, Germany) were annealed at 95°C, cooled and ligated into pJet1.2 (Invitrogen). Finally, the DNA fragments were amplified from the plasmid using pJet2.1-specific primers and blunted into the Fse1 restriction site of the vector plasmid. Depending on the orientation of the miR-1d target elements, the resulting plasmids were termed either pAAV-CMV-4xmiRT-1d-luc forward (fw) or pAAV-CMV-4xmiRT-1d-luc reverse (control). To generate the AAV vector plasmid containing the HSVtk suicide gene, the modified HSVtk gene termed SR39 was released by Bamh1/Not1 digest of pAAV-SR39 (ref. 43) and cloned into pAAV-CMV-luc, after the luciferase reporter had been enzymatically removed. The resulting plasmid was termed pAAV-CMV-4xmiRT-1d-HSVtk. All plasmids were controlled by sequence analysis (Seqlab, Göttingen, Germany).
AAV vector production and titration
Recombinant AAV vectors were produced by triple transfection of HEK293T cells with the respective helper plasmid encoding modified and wild-type rep and cap genes, the AAV vector plasmid containing luciferase or the HSVtk mutant SR39 (ref. 43) as well as miR-1d target elements (miRT-1d) and the adenoviral helper plasmid pXX6 (ref. 44) . Plasmids encoding the respective AAV capsid mutants were pXX2-ESGLSQS-187 for AAV2 (ref. 16) . The plasmids p5E18-VD2/9 and p5E18-VD2/9-SfiI1759 (ref. 25) were used to produce wild-type AAV9 vectors and the respective AAV9 capsid mutants. All transfections were performed by PolyFect transfection reagent (Qiagen, Hilden, Germany) following the manufacturer`s instructions. Vectors were purified by density gradient centrifugation 45 and genomic titers were determined by quantitative real-time PCR 46 as described before.
Analysis of luciferase transgene expression
For analysis of luciferase transgene expression in vivo, mice were anesthetized by gas inhalation (2% isoflurane, 98% oxygen) and recombinant AAV vectors were injected intravenously into the tail vein at a total volume of 200 μl PBS. In vivo bioluminescence imaging was performed using a Xenogen IVIS200 imaging system (Caliper Lifesciences, Mainz, Germany) after intraperitoneal injection of 200 μl D-luciferin firefly, potassium salt (150 mg kg − 1 ). Representative images were taken when luminescence (photons s cm − 2 ) reached the highest intensity. Luciferase activity in individual tissues was determined from snap frozen, homogenized tissues using Promega's luciferase assay (RLB) in a luminometer (Mithras LB 940, Berthold Technologies, Bad Wildbad, Germany). Values were normalized to protein levels determined by the Roti Nanoquant Protein assay (Roth, Karlsruhe, Germany).
Assessment of cardiotoxicity in mice treated with suicide gene vectors
To assess the cardiotoxicity of suicide gene vectors in vivo, 10-week-old female FVB/N mice were anesthetized and 5 × 10 11 vg of dual-targeted AAV9-ESGLSQS-miRT-1d-HSVtk, targeted AAV9-ESGLSQS-HSVtk or PBS were injected into the tail vein (n = 5 mice per group). Treatment with GCV (Cymeven, Roche, Mannheim, Germany; 80 mg kg − 1 body weight, i.p.) was started four days later and repeated four times. Two weeks after vector administration, left ventricular systolic function was assessed by echocardiography. Long axis (LAX) B-Mode cine loops as well as a short axis M-Mode images were obtained in hand restrained mice using the Vevo2100 System (Visualsonics, Toronto, ON, Canada) with the MS400 transducer (Visualsonics). Ejection fraction was measured using the LV-Trace function on at least three heartbeats in LAX B-Mode. Fractional shortening and left-ventricular enddiastolic diameter was obtained from M-Mode images measuring five consecutive heartbeats using the LV-Trace function. Three consecutive M-Mode measurements of the diastolic posterior wall thickness (PWTd) were performed. Mice were euthanized by cervical dislocation and weighed. Hearts were removed, washed in PBS and weighed. Atria were removed and both ventricles were cut along the SAX and flash frozen. The right hind limb was amputated at the femur level and incubated in a 37% hydrogen peroxide solution for 2 weeks. Tibia lengths were measured with a slide gauge. Statistical analyses were performed by one-way analysis of variance using the Tukey HSD test for post-analysis of variance comparison. P-values below 0.05 were considered significant.
Therapeutic suicide gene transfer For suicide gene transfer in vitro, 5 × 10 3 HeLa cells per well were seeded in 96-well plates and transduced with rAAV2-wildtype-4xmiRT-1d-HSVtk or rAAV2-wild-type-4xmiRT-1d-luc control vectors. After treatment with GCV (10 μM, 24 h and 72 h post transduction), the number of viable cells was measured by MTT assay (Sigma, St. Louis, MO, USA). For suicide gene delivery in vivo, 10-week-old female tumor-bearing PyMT mice were anesthetized and 5 × 10 11 vg of dual-targeted AAV9-ESGLSQS-miRT-1d-HSVtk, AAV9-wild-type-miRT-1d-HSVtk vectors or PBS were injected into the tail vein. GCV treatment was started 4 days later and repeated seven times (every second to third day). Tumor size was determined at indicated time points by caliper measurement.
Additional in vivo toxicity studies H4 heparin plasma obtained from treated and control mice was used for the analysis on Roche/Hitachi-Modular-Systems (Roche). Creatinine and ASAT were measured on P-modules. Creatinine was analyzed by the Jaffes-method (kinetic with compensation, 505 nm) and ASAT by the IFCC-methods (with activation by pyridoxa phosphate, UV-test). All analyses were carried out using IVD-certified tests and reagents following standard protocols provided by manufacturers (Roche). Morphological treatment effects of HSVtk therapy were visualized by hematoxylin and eosin staining of paraformaldehyde-fixed, paraffin embedded tissue sections.
Statistics
Data were expressed as mean ± s.e.m. If not indicated otherwise, statistical analysis was performed using GraphPad Prism program 3.0 (GraphPad Software, San Diego, CA, USA) by unpaired students-t test.
